If the cells you would like to access are currently listed as unavailable or you are ordering from outside of Europe please get in touch via Contact@EBiSC.org.

BIONi010-C-9

BIONi010-C CD33 KO

Gene-edited iPSC line

Not-for-profit fee: £1700 per vial
Available within next 12 months
Timepoint: Passage 1 post thaw, at confluency
Magnification: x4
Timepoint: Passage 1 post thaw, at confluency
Magnification: x10
A CLIP contains information about a cell line including any specific third party obligations relating to, for example, licensing obligations or the donor consent which affect the use of the cell line.

The EBiSC Access and Use Agreement must be completed along with an individual Cell Line Information Pack for each line. Complete the EAUA and send to Contact@EBiSC.org for countersignature. The EAUA must be fully signed before proceeding with your order.
A batch specific Certificate of Analysis will be available to download once you receive your EBiSC iPSC line.

General#

Cell Line

hPSCreg name BIONi010-C-9
Alternative name(s)
BIONi010-C CD33 KO
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines
BIONi010-C-5
(BIONi010-C CD33 E2del #N14 P26)
BIONi010-C-3
(BIONi010-C ApoE KO #KO30 P30)
BIONi010-C-25
(BIONi010-C heterozygous TREM2 KO)
BIONi010-C-17
(BIONi010-C TREM2 KO)
BIONi010-C
(BIONi010-C, K3P53)
BIONi010-C-2
(BIONi010-C ApoE E3/E3 #H8 P32)
BIONi010-C-70
(BIONi010-C with an APOE 2/2 genotype with an additional, homozygous christchurch mutation)
BIONi010-C-71
(BIONi010-C with an APOE 3/3 genotype with an additional, homozygous christchurch mutation)
BIONi010-C-4
(BIONi010-C ApoE E4/E4 #B44 P27)
BIONi010-C-6
(BIONi010-C ApoE E2/E2)
BIONi010-C-7
(BIONi010-C Trem2 R47H)
BIONi010-C-8
(BIONi010-C Trem2 T66M, #Y5-80)
BIONi010-C-13
(BIONi010-C + NGN2 #I7-26)
BIONi010-C-15
(BIONi010-C +dox inducible NGN2-GFP)
BIONi010-C-18
(BIONi010-C TBK1 KO)
BIONi010-C-51
(BIONi010-C TNNI3-mCherry reporter)
BIONi010-C-19
(BIONi010-C IKBKE KO)
BIONi010-C-10
(HNF1AP291fsinsC +/- 54-5)
BIONi010-C-11
(HNF1AP291fsinsC -/- 66-1)
BIONi010-C-12
(HNF4ApR309C -/- 2-4)
BIONi010-C-52
(BIONi010-C with an APOE 2/2 genotype (with two functional alleles in contrast to BIONi010-C-6))
BIONi010-C-53
(BIONi010-C with an APOE 3/3 genotype (with two functional alleles in contrast to BIONi010-C-2))
BIONi010-C-55
(BIONi010-C TNNI3-mCherry/TNNI1-EGFP dual reporter cl. 74)
BIONi010-C-24
(BIONi010-C Dox a-syn)
BIONi010-A
(K1P53)
BIONi010-B
(K2P53, BIONi010-B)
UKBi011-A-3
(ApoE 3/3)
Donor's gene variants:
APOE, APOE
Donor diseases:
Alzheimer disease
UKBi011-A-4
(ApoE 3/4)
Donor's gene variants:
APOE, APOE
Donor diseases:
Alzheimer disease
Notes KO for CD33. No larger chromosomal aberrations to be reported. Chr22: 1,4Mbp duplication in q11.23

Provider

Depositor Bioneer (BION)
Owner Bioneer (BION)
Distributors
EBiSC
Derivation country Denmark

External Databases

hPSCreg BIONi010-C-9
BioSamples SAMEA4454012
Cellosaurus CVCL_LL40
Wikidata Q54796783

General Information

Publications View all related publications on hPSCreg (2)
This EBiSC line can be used for:
Yes
Research use: allowed
Clinical use: no
Commercial use: no
Subclone of

Donor Information#

General Donor Information

Sex male
Ethnicity Black or African-American

Phenotype and Disease related information (Donor)

Diseases No disease was diagnosed.
Disease associated phenotypes no phenotypes

Karyotyping (Donor)

Has the donor karyotype been analysed?
Unknown

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

Donor Relations

Other cell lines of this donor

External Databases (Donor)

BioSamples SAMEA3105780

hIPSC Derivation#

General

The source cell information can be found in the parental cell line BIONi010-C.

Reprogramming method

Vector type Non-integrating
Vector Episomal
Genes
Is reprogramming vector detectable?
No

Vector free reprogramming

Other

Derived under xeno-free conditions
No
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions#

Latest released batch

Culture medium Essential E8
Passage method EDTA
Surface coating Matrigel / Geltrex
O2 concentration 18
CO2 concentration 5
Temperature 38
The following are the depositor culture conditions, they do not refer to any specific batch.
Surface coating Matrigel/Geltrex
Feeder cells
No
Passage method Enzyme-free cell dissociation
EDTA
O2 Concentration 18 %
CO2 Concentration 5 %
Medium Essential 8™
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
No

Characterisation#

Analysis of Undifferentiated Cells
Marker Present Absent
mCpG
OCT4
Morphology pictures
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
Mesoderm
Ont Id: UBERON_0000926
Ectoderm
Ont Id: UBERON_0000924

Microbiology / Virus Screening

HIV 1 Negative
HIV 2 Negative
Hepatitis B Negative
Hepatitis C Negative
Mycoplasma Negative

Genotyping#

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46 XY
Passage number: 25
Karyotyping method: G-Banding

Other Genotyping (Cell Line)

Is there genome-wide genotyping or functional data available?
Yes
Whole genome sequencing
https://ega-archive.org/studies/EGAS00001002755
This cell line has undergone WGS using the Illumina HiSeq X platform at 30x coverage. Fastq files are stored at the European Genome Archive, users can apply for access to this data by submitting an application form to the EBiSC Data Access Committee https://ega-archive.org/dacs/EGAC00001000768

Genetic Modification#

Disease/phenotype related modifications
Synonyms
  • AD
  • Alzheimer dementia
  • Alzheimer disease
  • Alzheimer's dementia
  • Alzheimer's disease
  • Alzheimers dementia
  • Alzheimers disease
  • presenile and senile dementia
  • Alzheimer disease, familial
show more synonyms
Genetic modifications
CD33 (target)
Gene knock-out
19q13.41
The CD33 gene has been knocked out. One base in exon one as well as 578 bases downstream (including whole exon 2) have been deleted. The basepair deletion leads to a frame shift. The larger deletion might not be necessary for a functional KO.
CRISPR-associated (CRISPR/Cas) System